📊 TELO Key Takeaways
Is Telomir Pharmaceuticals, Inc. (TELO) a Good Investment?
Telomir is a pre-revenue pharmaceutical development company with an annual operating cash burn of $1.8M, approximately 3 years of cash runway remaining. Despite improving loss metrics year-over-year, fundamental viability cannot be established without demonstrable product commercialization or revenue generation.
Telomir Pharmaceuticals, Inc. Key Strengths (TELO)
- Strong cash position relative to burn rate ($5.6M cash with $1.8M annual burn)
- Improving loss metrics (37% YoY improvement in net loss, 41% improvement in EPS)
- Minimal debt burden (0.02x Debt/Equity) provides financial flexibility
TELO Stock Risks: Telomir Pharmaceuticals, Inc. Investment Risks
- Pre-revenue company with no demonstrated commercial viability or revenue generation
- Negative returns on equity (-20%) and assets (-17%) indicate shareholder value destruction
- Unsustainable cash burn will deplete resources within approximately 3 years without revenue achievement
- High execution risk inherent to drug development (regulatory approval, clinical success probability unknown)
Key Metrics to Watch
- Revenue achievement and growth trajectory
- Operating cash flow burn rate and path to sustainability
- Cash runway in months remaining
- Pipeline advancement (clinical trial results, regulatory milestone achievements)
Telomir Pharmaceuticals, Inc. (TELO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 7.00x current ratio provides a solid financial cushion.
TELO Profit Margin, ROE & Profitability Analysis
TELO vs Healthcare Sector: How Telomir Pharmaceuticals, Inc. Compares
How Telomir Pharmaceuticals, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Telomir Pharmaceuticals, Inc. Stock Overvalued? TELO Valuation Analysis 2026
Based on fundamental analysis, Telomir Pharmaceuticals, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Telomir Pharmaceuticals, Inc. Balance Sheet: TELO Debt, Cash & Liquidity
TELO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Telomir Pharmaceuticals, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.56 indicates the company is currently unprofitable.
TELO Revenue Growth, EPS Growth & YoY Performance
Telomir Pharmaceuticals, Inc. Dividends, Buybacks & Capital Allocation
TELO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Telomir Pharmaceuticals, Inc. (CIK: 0001971532)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TELO
What is the AI rating for TELO?
Telomir Pharmaceuticals, Inc. (TELO) has an AI grade of C with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TELO's key strengths?
Claude: Strong cash position relative to burn rate ($5.6M cash with $1.8M annual burn). Improving loss metrics (37% YoY improvement in net loss, 41% improvement in EPS).
What are the risks of investing in TELO?
Claude: Pre-revenue company with no demonstrated commercial viability or revenue generation. Negative returns on equity (-20%) and assets (-17%) indicate shareholder value destruction.
What is TELO's revenue and growth?
Telomir Pharmaceuticals, Inc. reported revenue of N/A.
Does TELO pay dividends?
Telomir Pharmaceuticals, Inc. does not currently pay dividends.
Where can I find TELO SEC filings?
Official SEC filings for Telomir Pharmaceuticals, Inc. (CIK: 0001971532) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TELO's EPS?
Telomir Pharmaceuticals, Inc. has a diluted EPS of $-0.03.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TELO's fundamental grade?
Based on our AI fundamental analysis in June 2026, Telomir Pharmaceuticals, Inc. has a C grade with 78% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TELO stock overvalued or undervalued?
Valuation metrics for TELO: ROE of -20.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TELO's AI grade for 2026?
Our dual AI analysis gives Telomir Pharmaceuticals, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TELO's free cash flow?
Telomir Pharmaceuticals, Inc.'s operating cash flow is $-1.8M, with capital expenditures of N/A.
How does TELO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -20.0% (avg: 15%), current ratio 7.00 (avg: 2).